New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
Conclusion
In patients with a recent acute coronary syndrome, the addition of a new oral anticoagulant to antiplatelet therapy results in a modest reduction in cardiovascular events but a substantial increase in bleeding, most pronounced when new oral anticoagulants are combined with dual antiplatelet therapy.
Source: European Heart Journal - Category: Cardiology Authors: Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., Sundstrom, J. Tags: Acute coronary syndromes Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Databases & Libraries | Heart | Heart Attack | Ischemic Stroke | Plavix | Pradaxa | Stroke | Study